Upregulated microRNA-16 as an oncogene in renal cell carcinoma

Chen,Duqun; Li,Yifan; Yu,Zuhu; Su,Zhengming; Yu,Wenshui; Li,Yuchi; Yang,Shangqi; Gui,Yaoting; Ni,Liangchao; Lai,Yongqing

doi:10.3892/mmr.2015.3496

Upregulated microRNA-16 as an oncogene in renal cell carcinoma

Authors:
- Duqun Chen
- Yifan Li
- Zuhu Yu
- Zhengming Su
- Wenshui Yu
- Yuchi Li
- Shangqi Yang
- Yaoting Gui
- Liangchao Ni
- Yongqing Lai
View Affiliations

Affiliations: Department of Urology, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, P.R. China, Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, Institute of Urology, Shenzhen PKU‑HKUST Medical Center, Shenzhen, Guangdong 518036, P.R. China
Published online on: March 17, 2015 https://doi.org/10.3892/mmr.2015.3496
Pages: 1399-1404

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNAs (miRs) are small, endogenous noncoding RNAs that serve a significant function in various biologic processes, including those involved in cancer. The present study aimed to determine the expression and function of miR‑16 in renal cell carcinoma (RCC). Quantitative polymerase chain reaction was used to quantify the expression of miR‑16 in 48 paired RCC tissues and adjacent normal tissues. The impact of miR‑16 on cell proliferation, migration and apoptosis was analyzed by transfecting miR‑16 mature molecules into the renal cancer cell lines 786‑O and ACHN. The results indicated that miR‑16 was significantly upregulated in RCC tissues (P<0.05). Downregulation of miR‑16 resulted in reduced cell proliferation and migration and increased levels of apoptosis, while overexpression of miR‑16 resulted in accelerated cellular proliferation and migration, suggesting that miR‑16 may function as an oncogene in RCC. The present study demonstrated for the first time, to the best of our knowledge, that miR‑16 is upregulated in RCC and acts as an oncogene by inducing cellular proliferation, migration and reducing apoptosis. Further study of miR‑16 in RCC may clarify the molecular mechanisms of RCC carcinogenesis and aid in the development of novel biomarkers and therapeutic options.

View Figures

View References

1	Cairns P: Renal cell carcinoma. Cancer Biomark. 9:461–473. 2010.
2	Kroeze SG, Bijenhof AM, Bosch JL and Jans JJ: Diagnostic and prognostic tissuemarkers in clear cell and papillary renal cell carcinoma. Cancer Biomark. 7:261–268. 2010.PubMed/NCBI
3	Pischon T, Lahmann PH, Boeing H, et al: Body size and risk of renal cell carcinoma in the European prospective investigation into cancer and nutrition (EPIC). Int J Cancer. 118:728–738. 2006. View Article : Google Scholar
4	Eichelberg C, Junker K, Ljungberg B and Moch H: Diagnostic and prognostic molecular markers for renal cell carcinoma: a critical appraisal of the current state of research and clinical applicability. Eur Urol. 55:851–863. 2009. View Article : Google Scholar : PubMed/NCBI
5	Cimmino A, Calin GA, Fabbri M, et al: miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA. 102:13944–13949. 2005. View Article : Google Scholar : PubMed/NCBI
6	Wulfken LM, Moritz R, Ohlmann C, et al: MicroRNAs in renal cell carcinoma: diagnostic implications of serum miR-1233 levels. PLoS One. 6:e257872011. View Article : Google Scholar : PubMed/NCBI
7	Sana J, Faltejskova P, Svoboda M and Slaby O: Novel classes of non-coding RNAs and cancer. J Transl Med. 10:1032012. View Article : Google Scholar : PubMed/NCBI
8	Calin GA, Dumitru CD, Shimizu M, et al: Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 99:15524–15529. 2002. View Article : Google Scholar : PubMed/NCBI
9	Gao X, Zhang R, Qu X, et al: MiR-15a, miR-16-1 and miR-17-92 cluster expression are linked to poor prognosis in multiple myeloma. Leuk Res. 36:1505–1509. 2012. View Article : Google Scholar : PubMed/NCBI
10	Bottoni A, Piccin D, Tagliati F, et al: miR-15a and miR-16-1 down-regulation in pituitary adenomas. J Cell Physiol. 204:280–285. 2005. View Article : Google Scholar : PubMed/NCBI
11	Teshima K, Nara M, Watanabe A, et al: Dysregulation of BMI1 and microRNA-16 collaborate to enhance an anti-apoptotic potential in the side population of refractory mantle cell lymphoma. Oncogene. 33:2191–2203. 2014. View Article : Google Scholar
12	Bandi N, Zbinden S, Gugger M, et al: miR-15a and miR-16 are implicated in cell cycle regulation in a Rb-dependent manner and are frequently deleted or down-regulated in non-small cell lung cancer. Cancer Res. 69:5553–5559. 2009. View Article : Google Scholar : PubMed/NCBI
13	Porkka KP, Ogg EL, Saramäki OR, et al: The miR-15a-miR-16-1 locus is homozygously deleted in a subset of prostate cancers. Genes Chromosomes Cancer. 50:499–509. 2011. View Article : Google Scholar : PubMed/NCBI
14	Schmittgen TD and Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
15	Yi Z, Fu Y, Zhao S, Zhang X and Ma C: Differential expression of miRNA patterns in renal cell carcinoma and nontumorous tissues. J Cancer Res Clin Oncol. 136:855–862. 2010. View Article : Google Scholar
16	Jung M, Mollenkopf HJ, Grimm C, et al: MicroRNA profiling of clear cell renal cell cancer identifies a robust signature to define renal malignancy. J Cell Mol Med. 13:3918–3928. 2009. View Article : Google Scholar : PubMed/NCBI
17	Kosari F, Parker AS, Kube DM, et al: Clear cell renal cell carcinoma: gene expression analyses identify a potential signature for tumor aggressiveness. Clin Cancer Res. 11:5128–5139. 2005. View Article : Google Scholar : PubMed/NCBI
18	Shenouda SK and Alahari SK: MicroRNA function in cancer: oncogene or a tumor suppressor? Cancer Metastasis Rev. 28:369–378. 2009. View Article : Google Scholar : PubMed/NCBI
19	Zhang B, Pan X, Cobb GP and Anderson TA: microRNAs as oncogenes and tumor suppressors. Dev Biol. 302:1–12. 2007. View Article : Google Scholar
20	Xia L, Zhang D, Du R, et al: miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer. 123:372–379. 2008. View Article : Google Scholar : PubMed/NCBI
21	Guo CJ, Pan Q, Li DG, Sun H and Liu BW: miR-15b and miR-16 are implicated in activation of the rat hepatic stellate cell: An essential role for apoptosis. J Hepatol. 50:766–778. 2009. View Article : Google Scholar : PubMed/NCBI
22	Bonci D, Coppola V, Musumeci M, et al: The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med. 14:1271–1277. 2008. View Article : Google Scholar : PubMed/NCBI
23	Brugarolas J: PBRM1 and BAP1 as novel targets for renal cell carcinoma. Cancer J. 19:324–332. 2013. View Article : Google Scholar : PubMed/NCBI
24	Gossage L, Murtaza M, Slatter AF, et al: Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A and JARID1c in clear cell renal cell carcinoma. Genes Chromosomes Cancer. 53:38–51. 2014. View Article : Google Scholar
25	Kapur P, Christie A, Raman JD, et al: BAP1 immunohistochemistry predicts outcomes in a multi-institutional cohort with clear cell renal cell carcinoma. J Urol. 191:603–610. 2014. View Article : Google Scholar
26	Kalinowski FC, Brown RA, Ganda C, et al: microRNA-7: A tumor suppressor miRNA with therapeutic potential. Int J Biochem Cell Biol. 54:312–317. 2014. View Article : Google Scholar : PubMed/NCBI
27	Yu Z, Ni L, Chen D, et al: Identification of miR-7 as an oncogene in renal cell carcinoma. J Mol Histol. 44:669–677. 2013. View Article : Google Scholar : PubMed/NCBI
28	Schaefer A, Jung M, Kristiansen G, et al: MicroRNAs and cancer: Current state and future perspectives in urologic oncology. Urol Oncol. 28:4–13. 2010. View Article : Google Scholar
29	Wang Y, Gu J, Roth JA, et al: Pathway-based serum microRNA profiling and survival in patients with advanced stage non-small cell lung cancer. Cancer Res. 73:4801X–4809. 2013. View Article : Google Scholar
30	Delfino KR and Rodriguez-Zas SL: Transcription factor-microRNA-target gene networks associated with ovarian cancer survival and recurrence. PLoS One. 8:e586082013. View Article : Google Scholar : PubMed/NCBI
31	Reid G, Pel ME, Kirschner MB, et al: Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma. Ann Oncol. 24:3128–3155. 2013. View Article : Google Scholar : PubMed/NCBI